Life Healthcare Group Holdings Limited provided group earnings guidance for the full year ended September 30, 2018. For the period, the company expected revenue to be in the range of ZAR 22,877 million to ZAR 23,709 million and normalized EBITDA to be in the range of ZAR 5,401 million to ZAR 5,551 million. EPS for the year ended 30 September 2018 is expected to be between 103.9 cents per share (cps) and 110.1 cps, a growth of between 67.0% and 77.0% above the prior year reported EPS of 62.2 cps. Earnings in the current year have been impacted by the following: improved overall performance of the business; the inclusion of Alliance Medical results for 12 months (2017: 10.3 months); the subsequent acquisitions by Alliance Medical; the weakening of the rand against the British Pound, Euro and Polish Zloty; the results reflect a gain of approximately ZAR 74 million (2017: loss of ZAR 65 million) relating to the acquisition by Life Healthcare of the minority shareholding in Alliance Medical; the prior year includes the non-recurring impact of a number of once-off items, such as: costs related to the Alliance Medical acquisition (principally transaction costs of ZAR 267 million and funding costs of ZAR 427 million); and the impairment of the Scanmed S.A. business in Poland (ZAR 167 million). The improvement in earnings has been partially offset by: the increase in the amortization of intangible assets related to the Alliance Medical business included for 12 months while the amortization charge was only for 10.3 months in the comparable year; and the weighted number of shares in issue in the current year increased by roughly 10.8% due to the effect of the rights offer shares issued in April 2017 as well as the scrip distribution shares issued during the current year. HEPS is expected to be between 104.5 cps and 112.2 cps, a growth of between 35.0% and 45.0% above the prior year reported HEPS of 77.4 cps. HEPS in the current year excludes the impact of impairments as well as the profit on sale of property, plant and equipment (PPE) mainly in southern Africa. In the prior year, HEPS excluded the Polish impairment of ZAR 167 million and the loss on disposal of PPE.